320 related articles for article (PubMed ID: 32735546)
1. The Anatomy of the SARS-CoV-2 Biomedical Literature: Introducing the CovidX Network Algorithm for Drug Repurposing Recommendation.
Gates LE; Hamed AA
J Med Internet Res; 2020 Aug; 22(8):e21169. PubMed ID: 32735546
[TBL] [Abstract][Full Text] [Related]
2. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Uzunova K; Filipova E; Pavlova V; Vekov T
Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
[TBL] [Abstract][Full Text] [Related]
3. Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19.
Norinder U; Tuck A; Norgren K; Munic Kos V
Biomed Pharmacother; 2020 Oct; 130():110582. PubMed ID: 32763818
[TBL] [Abstract][Full Text] [Related]
4. Drug repositioning is an alternative for the treatment of coronavirus COVID-19.
Serafin MB; Bottega A; Foletto VS; da Rosa TF; Hörner A; Hörner R
Int J Antimicrob Agents; 2020 Jun; 55(6):105969. PubMed ID: 32278811
[TBL] [Abstract][Full Text] [Related]
5. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic.
Tripathy S; Dassarma B; Roy S; Chabalala H; Matsabisa MG
Int J Antimicrob Agents; 2020 Aug; 56(2):106028. PubMed ID: 32450198
[TBL] [Abstract][Full Text] [Related]
6. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Martinez MA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
[TBL] [Abstract][Full Text] [Related]
7. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
[TBL] [Abstract][Full Text] [Related]
8. Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines.
Vitte J; Michel M; Mezouar S; Diallo AB; Boumaza A; Mege JL; Desnues B
Front Immunol; 2020; 11():2159. PubMed ID: 32983179
[TBL] [Abstract][Full Text] [Related]
9. Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review.
Rodrigo C; Fernando SD; Rajapakse S
Clin Microbiol Infect; 2020 Aug; 26(8):979-987. PubMed ID: 32470568
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.
Meo SA; Klonoff DC; Akram J
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4539-4547. PubMed ID: 32373993
[TBL] [Abstract][Full Text] [Related]
11. Chloroquine and its derivatives in the management of COVID-19: A scoping review.
Pimentel J; Andersson N
Biomedica; 2020 Oct; 40(Supl. 2):80-95. PubMed ID: 33152192
[TBL] [Abstract][Full Text] [Related]
12. SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19.
Fiscon G; Conte F; Farina L; Paci P
PLoS Comput Biol; 2021 Feb; 17(2):e1008686. PubMed ID: 33544720
[TBL] [Abstract][Full Text] [Related]
13. COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help.
Lentini G; Cavalluzzi MM; Habtemariam S
Molecules; 2020 Apr; 25(8):. PubMed ID: 32316270
[TBL] [Abstract][Full Text] [Related]
14. Repurposing antimalarials and other drugs for COVID-19.
Schlagenhauf P; Grobusch MP; Maier JD; Gautret P
Travel Med Infect Dis; 2020; 34():101658. PubMed ID: 32247925
[No Abstract] [Full Text] [Related]
15. Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings.
Abena PM; Decloedt EH; Bottieau E; Suleman F; Adejumo P; Sam-Agudu NA; Muyembe TamFum JJ; Seydi M; Eholie SP; Mills EJ; Kallay O; Zumla A; Nachega JB
Am J Trop Med Hyg; 2020 Jun; 102(6):1184-1188. PubMed ID: 32323646
[TBL] [Abstract][Full Text] [Related]
16. Current pharmacological treatments for SARS-COV-2: A narrative review.
Nittari G; Pallotta G; Amenta F; Tayebati SK
Eur J Pharmacol; 2020 Sep; 882():173328. PubMed ID: 32603692
[TBL] [Abstract][Full Text] [Related]
17. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect.
Andreani J; Le Bideau M; Duflot I; Jardot P; Rolland C; Boxberger M; Wurtz N; Rolain JM; Colson P; La Scola B; Raoult D
Microb Pathog; 2020 Aug; 145():104228. PubMed ID: 32344177
[TBL] [Abstract][Full Text] [Related]
18. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
[TBL] [Abstract][Full Text] [Related]
19. Old and re-purposed drugs for the treatment of COVID-19.
Jean SS; Hsueh PR
Expert Rev Anti Infect Ther; 2020 Sep; 18(9):843-847. PubMed ID: 32419524
[No Abstract] [Full Text] [Related]
20. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
